U.S. Biotechnology Stock News
Categories
- All
- Editor's Picks
- Q&A with Gurus
- Gurus' Stock Picks
- Insider Transaction
- Earning Reports
- CEO Shareholder Letters
- Press Release
- Earnings Call Transcripts
- Podcast
Industries
- Aerospace & Defense
- Agriculture
- Asset Management
- Banks
- Beverages - Alcoholic
- Beverages - Non-Alcoholic
- Biotechnology
- Building Materials
- Business Services
- Capital Markets
- Chemicals
- Conglomerates
- Construction
- Consumer Packaged Goods
- Credit Services
- Diversified Financial Services
- Drug Manufacturers
- Education
- Farm & Heavy Construction Machinery
- Forest Products
- Furnishings, Fixtures & Appliances
- Hardware
- Healthcare Plans
- Healthcare Providers & Services
- Homebuilding & Construction
- Industrial Distribution
- Industrial Products
- Insurance
- Interactive Media
- Manufacturing - Apparel & Accessories
- Media - Diversified
- Medical Devices & Instruments
- Medical Diagnostics & Research
- Medical Distribution
- Metals & Mining
- Oil & Gas
- Other Energy Sources
- Packaging & Containers
- Personal Services
- Real Estate
- REITs
- Restaurants
- Retail - Cyclical
- Retail - Defensive
- Semiconductors
- Software
- Steel
- Telecommunication Services
- Tobacco Products
- Transportation
- Travel & Leisure
- Utilities - Independent Power Producers
- Utilities - Regulated
- Vehicles & Parts
- Waste Management
GuruFocus News Biotechnology Tarsus Pharmaceuticals Inc (TARS) Q3 2024 Earnings Call Highlights: Record Sales and Strategic Expansions
Tarsus Pharmaceuticals Inc (TARS) reports its most successful quarter with $48 million in net sales, expanded coverage, and a growing sales force. Nov 14, 2024
GuruFocus News Biotechnology scPharmaceuticals Inc (SCPH) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic Expansions Amidst Financial Challenges
scPharmaceuticals Inc (SCPH) reports a 24% revenue increase and strategic advancements, despite facing significant net losses and operational hurdles. Nov 14, 2024
GuruFocus News Biotechnology Omeros Corp (OMER) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Adjustments
Omeros Corp (OMER) reports reduced net loss and strategic progress in clinical programs, despite financial challenges and market competition. Nov 14, 2024
GuruFocus News Biotechnology Vaxart Inc (VXRT) Q3 2024 Earnings Call Highlights: Advancements in Oral Vaccine Platform and Financial Growth
Vaxart Inc (VXRT) reports significant progress in its COVID-19 and Norovirus programs, backed by strong governmental support and increased revenue. Nov 14, 2024
GuruFocus News Biotechnology BioCardia Inc (BCDA) Q3 2024 Earnings Call Highlights: Breakthroughs and Challenges in Cardiac Cell Therapy
BioCardia Inc (BCDA) secures FDA approvals and funding, but faces market and regulatory hurdles. Nov 14, 2024
GuruFocus News Biotechnology Liquidia Corp (LQDA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst Regulatory Challenges
Liquidia Corp (LQDA) outlines promising clinical progress and strategic partnerships while navigating regulatory and financial hurdles. Nov 14, 2024
GuruFocus News Biotechnology Seres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: Strategic Moves and Clinical Progress Amid Financial Challenges
Seres Therapeutics Inc (MCRB) reports promising clinical results and strategic financial maneuvers, despite facing increased net losses and operational uncertainties. Nov 14, 2024
GuruFocus News Biotechnology Jaguar Health Inc (JAGX) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic Advances Amidst Operational Challenges
Jaguar Health Inc (JAGX) reports increased revenue and strategic product launches, while navigating financial losses and regulatory hurdles. Nov 14, 2024
GuruFocus News Biotechnology ARS Pharmaceuticals Inc (SPRY) Q3 2024 Earnings Call Highlights: Strong Cash Position and NEPHI Launch Amidst Initial Challenges
Despite a net loss, ARS Pharmaceuticals Inc (SPRY) is optimistic about NEPHI's market potential and strategic global expansion. Nov 14, 2024
GuruFocus News Biotechnology Fulcrum Therapeutics Inc (FULC) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst Financial Challenges
Despite a strong cash position and promising pipeline developments, Fulcrum Therapeutics Inc (FULC) faces hurdles with reduced revenues and ongoing net losses. Nov 14, 2024
GuruFocus News Biotechnology Acurx Pharmaceuticals Inc (ACXP) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
Acurx Pharmaceuticals Inc (ACXP) reports promising clinical trial results and patent gains, while navigating cash flow and partnership hurdles. Nov 14, 2024
GuruFocus News Biotechnology X4 Pharmaceuticals Inc (XFOR) Q3 2024 Earnings Call Highlights: Strategic Engagement and Financial Resilience
X4 Pharmaceuticals Inc (XFOR) reports strong market engagement and financial stability, despite initial sales challenges for Maverick. Nov 14, 2024
GuruFocus News Biotechnology Mersana Therapeutics Inc (MRSN) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial Resilience
Mersana Therapeutics Inc (MRSN) reports significant financial improvements and promising clinical trial progress, positioning the company for future growth. Nov 14, 2024
GuruFocus News Biotechnology Q3 2024 Tarsus Pharmaceuticals Inc Earnings Call Transcript
Nov 14, 2024
GuruFocus News Biotechnology Q3 2024 Taysha Gene Therapies Inc Earnings Call Transcript
Nov 14, 2024
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers